Home » Opinion » Foreign Views
Consumers should plan to pay more for medicine
Print Edition
Healthcare spending, currently projected to grow by 5.8 percent annually in the US and to represent 20.1 percent of the total economy by 2025, has made healthcare market reforms a critical and ongoing priority of regulatory policy.
Healthcare markets are intrinsically fragile simply because providers deliver wide-ranging services to generally ill-informed patients who cover only a fraction of the costs.
To fill the gap, in what appears to be a failing market coordination between providers and patients, intermediaries have been responding by injecting know-how, aggregating demand and screening supplies. But intermediaries are subject to regulatory concerns, as non-transparent practices could give rise to deceptive conduct and the scale of operations may eliminate actual, or foreclose potential, competition. Pharmacy benefit managers (PBMs) are a case in point.
PBMs organize the sale and reimbursement of prescription drugs between producers, pharmacists and health plans. At the end of 2016, around 30 PBMs were managing pharmacy benefits for more than 253 million Americans.
But since the late 1990s, PBMs have been increasingly merging with large pharmacies, leading to concerns over their incentives to secure the best deal for patients.
PBMs are also the focal point in the current “drug-price blame game”, with independent pharmacists and drug producers zeroing in on them as the main culprits for price increases.
PBMs’ use of the maximum allowable costs (MAC) price list model, which specifies the maximum amount that a buyer will pay for generic drugs, has been controversial since its introduction in the 1980s.
The theory is that PBMs set MACs based on the average acquisition cost of a benchmark pharmacy, thus finding a middle ground that simplifies transactions, avoids the distortions of commission-based pricing, and prompts pharmacists to shop around for the cheapest generics. However, PBMs are not required to be open about their methods for setting MAC pricing, leading to mistrust over how they are calculated and suspicion that MACs are being effectively rigged to benefit the big pharmacy companies for whom some of these PBMs work.
Added to this is further mistrust, this time of the FTC to carry out its duties as the federal antitrust enforcer. The American Antitrust Institute, a competition think-tank, believes the US has become too lax on competition in recent years, leading to cartelization in the healthcare markets. State legislators therefore don’t trust the federal commission to do its job and feel they must act to rein in the actions of predatory, often out-of-state PBMs. Mississippi, for example, has introduced legislative changes that move regulatory control of PBMs from the Insurance Commission to the state’s Board of Pharmacy, which is made up of pharmacists with no fiduciary duty. This will force PBMs to disclose how they arrive at MACs and may also penalize them if amounts paid and charged differ. This may have some positive effect on local pharmacies’ bottom lines, but in effect it removes the market forces that, on aggregate, benefit the US consumer by keeping drug prices in check.
As yet, there is no evidence that PBMs actually need to be brought into check. Although antitrust litigations have been brought against some PBMs, there have been no definitive verdicts against them. Evidently, issues are unclear and regulatory responses far from obvious.
The problem with protective legislation is that it destroys the whole PBM model. It eliminates efficiency incentives, limits competition among pharmacies and drug suppliers and lessens rivalry among PBMs. Local constituencies are driving state regulation at the expense of consumers and out-of-state big business. The likely outcome is that competition will be negatively affected — and drug prices will rise.
Ralf Boscheck is the Lundin Family Professor of Economics and Business Policy at IMD business school, where he is program director of IMD’s MBA program. Shanghai Daily condensed the article.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
